Who are Polymyxin e's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Standard Dose Colistin, Coly Mycin M Injectable Product, Ceftazidime-avibactam + Colistin/Polymyxin B, High Dose Colistin, Colistin/Polymyxin B + Sulbactam, Colistin and saline solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/polymyxin-e.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Polymyxin e — Competitive Intelligence Brief

Polymyxin e (Polymyxin e) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polymyxin antibiotic. Area: Infectious Disease.

marketed Polymyxin antibiotic Bacterial lipopolysaccharides and phospholipids Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Polymyxin e (Polymyxin e) — Mahmoud I Mostafa. Polymyxin E (colistin) disrupts bacterial cell membranes by binding to lipopolysaccharides and phospholipids, causing cell lysis and death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Polymyxin e TARGET	Polymyxin e	Mahmoud I Mostafa	marketed	Polymyxin antibiotic	Bacterial lipopolysaccharides and phospholipids
Standard Dose Colistin	Standard Dose Colistin	King Saud Medical City	marketed	Polymyxin antibiotic	Bacterial lipopolysaccharides and phospholipids
Coly Mycin M Injectable Product	Coly Mycin M Injectable Product	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Polymyxin antibiotic	Bacterial lipopolysaccharides and phospholipids
Ceftazidime-avibactam + Colistin/Polymyxin B	Ceftazidime-avibactam + Colistin/Polymyxin B	National University of Singapore	marketed	Beta-lactam/beta-lactamase inhibitor + polymyxin antibiotic combination	Bacterial peptidoglycan cross-linking enzymes (PBPs); beta-lactamases; bacterial cell membrane lipopolysaccharide and phospholipids
High Dose Colistin	High Dose Colistin	King Saud Medical City	marketed	Polymyxin antibiotic	Bacterial lipopolysaccharide (LPS) and outer membrane
Colistin/Polymyxin B + Sulbactam	Colistin/Polymyxin B + Sulbactam	National University of Singapore	marketed	Polymyxin antibiotic + β-lactamase inhibitor combination	Bacterial cell membrane (polymyxins); bacterial β-lactamases (sulbactam)
Colistin and saline solution	Colistin and saline solution	Hospitales Universitarios Virgen del Rocío	phase 3	Polymyxin antibiotic	Bacterial lipopolysaccharide (LPS) and cell membrane

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polymyxin antibiotic class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
King Saud Medical City · 2 drugs in this class
Hospitales Universitarios Virgen del Rocío · 1 drug in this class
Mahmoud I Mostafa · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Vanderbilt University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Polymyxin e — Competitive Intelligence Brief. https://druglandscape.com/ci/polymyxin-e. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab